Vyome (HIND) vs Palatin Technologies (PTN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Palatin Technologies (PTN) has outperformed Vyome (HIND) over the past year, gaining 19.4% versus a loss of 62.0%. Over five years, PTN leads with a -98.4% price change compared with -100.0% for HIND. Palatin Technologies is the larger company by market cap ($15.3 million vs $14.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HIND | PTN |
|---|---|---|
| Share price | $2.09 | $8.60 |
| Market cap | $14.67M | $15.32M |
| 1-day change | +2.96% | -4.55% |
| YTD return | -39.24% | -44.08% |
| 1-year return | -62.00% | +19.44% |
| 5-year return | -100.00% | -98.40% |
| P/E ratio (TTM) | 1.17 | — |
| EPS (TTM) | $1.78 | $-3.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.56 | $31.00 |
| 52-week low | $1.75 | $5.61 |
| Distance from 52-week high | -68.14% | -72.26% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +322.49% | +522.09% |
| Average volume | 13.18K | 63.25K |
| Shares outstanding | 7.02M | 1.78M |
| Employees | 9 | 25 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PTN has outperformed HIND by 81.4 percentage points over the past year.
About Vyome
HIND stock →Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States. It operates through Pharmaceutical and Biotechnology segments.
Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees
About Palatin Technologies
PTN stock →Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity completed Phase 2 clinical trial; completed a phase 2 of diabetic nephropathy It also provides pl9643 for dry eye disease; and oral PL8177 for inflammatory bowel diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 25 employees
HIND vs PTN FAQ
Which is bigger, Vyome or Palatin Technologies?
Palatin Technologies (PTN) is larger, with a market capitalization of $15.32M compared with $14.67M for Vyome (HIND).
Which stock has performed better over the past year, HIND or PTN?
PTN returned +19.44% over the past 12 months, compared with -62.00% for HIND (price return, excluding dividends). Past performance does not predict future results.
Are Vyome and Palatin Technologies in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.